Abstracts tagged "Cardiovascular disease"

Abstract Number: 1563 • 2015 ACR/ARHP Annual Meeting
Dyslipidemia and Hyperglycemia, Two Cardiometabolic Parameters, Independently Predict Poor Outcome in Early Rheumatoid Arthritis: Results from Espoir Cohort
Claire I. Daien¹, Jeremie Sellam², Nathalie Rincheval³, Bruno Fautrel⁴, Alain Saraux⁵, Francis Berenbaum⁶, Jacques Morel¹, Jean-Pierre Daures⁷ and Bernard Combe⁸, ¹Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Department of Rheumatology, Assistance Publique – Hôpitaux de Paris, Saint-Antoine Hospital, Paris, France, ³Biostatistic, EA 2415, Epidemiology unit, Montpellier, France, ⁴Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁶Rheumatology and Paris VI University, Saint-Antoine Hospital, Paris, France, ⁷Biostatistic, EA 2415 Epidemiology unit, Montpellier, France, ⁸Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Previous studies showed that obesity in patients with rheumatoid arthritis (RA) is associated with higher disease activity. Beyond obesity, cardiometabolic disturbances may impact the…
Abstract Number: 1972 • 2015 ACR/ARHP Annual Meeting
Cardiovascular and Cerebrovascular Disease and Social Deprivation in Patients with Giant Cell Arteritis
Joanna Robson¹, Amit Kiran², Andrew Hutchings³, Joseph Maskell⁴, Nigel K Arden⁵, Willie Hamilton⁶, Bhaskar Dasgupta^7,8 and Raashid Luqmani⁹, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ³Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, ⁴Faculty of Medicine, University of Southampton, Southampton, United Kingdom, ⁵Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁶Primary Care, University of Exeter, Exeter, United Kingdom, ⁷Southend University Hospital, Southend, United Kingdom, ⁸Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in the UK, with an incidence of 2.2 cases per 10,000 person-years. Cerebrovascular…
Abstract Number: 2892 • 2015 ACR/ARHP Annual Meeting
Statin Treatment in Patients with Ankylosing Spondylitis
Grunde Wibetoe¹, Eirik Ikdahl¹, Tore K. Kvien², Silvia Rollefstad¹ and Anne Grete Semb³, ¹Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD). In the general population, CVD risk reduction can be achieved by lipid…
Abstract Number: 231 • 2015 ACR/ARHP Annual Meeting
Uric Acid Levels Predict Mortality in Women
Jenni E Kauppi¹, Tuomo Nieminen^2,3, Mika Kähönen^4,5, Anne Kerola⁶, Antti Jula⁷, Jaana Leiviskä⁸ and Markku J. Kauppi^9,10, ¹School of medicine, University of Tampere, Tampere, Finland, ²Department of Internal Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ³Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, ⁴Department of Clinical physiology, School of Medicine, University of Tampere, Tampere, Finland, ⁵Department of Clinical Physiology, Medical Imaging Centre, Pirkanmaa Hospital District, Tampere, Finland, ⁶Faculty of Medicine, University of Helsinki, Helsinki, Finland, ⁷Department of Health, National Institute for Health and Welfare, Turku, Finland, ⁸Department of Health, National Institute for Health and Welfare, Helsinki, Finland, ⁹School of Medicine, University of Tampere, Tampere, Finland, ¹⁰Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland
Background/Purpose: Hyperuricemia induces chronic inflammation and is associated with many diseases such as metabolic syndrome, high blood pressure, chronic kidney disease and cardiovascular diseases. The…
Abstract Number: 1503 • 2015 ACR/ARHP Annual Meeting
A Systematic Screening of Comorbidities By the Rheumatologist in Inflammatory Rheumatisms Impacts Chronic Disease Care
Claire I. Daien¹, Amandine Tubery², Guilhem du Cailar³, Aurore Royanez⁴, Thibault Mura⁵, Marie-Christine Picot⁶, Rodolphe Bourret⁷, François Roubille⁸, Jean Bousquet⁹, Jacques Morel¹, Pierre Fesler³ and Bernard Combe¹⁰, ¹Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Nîmes University Hospital, Rheumatology Department, Nimes, France, ³Internal Medicine and Hypertension, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology and Pharmacology, Montpellier, France, ⁵CIC, Hopital Gui De Chauliac, Montpellier, France, ⁶DIM, Montpellier, France, ⁷Direction Teaching hospital, Montpellier, France, ⁸Cardiology, Montpellier, France, ⁹Pneumology, Montpellier, France, ¹⁰Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Patients with inflammatory rheumatisms especially rheumatoid arthritis (RA) have a greater risk of cardiovascular diseases (CVD), infections, chronic respiratory diseases (CRD) and osteoporosis. As…
Abstract Number: 1566 • 2015 ACR/ARHP Annual Meeting
The Impact of Severe Extra-Articular Manifestations and Patient Reported Outcome Measures on Cardiovascular Disease in Rheumatoid Arthritis
Lisa Theander¹, Jan-Åke Nilsson¹, Minna Willim^1,2, Britt-Marie Nyhäll-Wåhlin^1,3, Lennart T.H. Jacobsson^1,4 and Carl Turesson^1,5, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ³Department of Rheumatology, Falun Hospital, Falun, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, ⁵Lund University, Rheumatology, Dept. of Clinical Sciences,, Malmö, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiovascular disease (CVD). Disease severity, including extra-articular rheumatoid arthritis (ExRA) manifestations, has previously been demonstrated…
Abstract Number: 1974 • 2015 ACR/ARHP Annual Meeting
Do Patients with Giant Cell Arteritis Meet the 2011 United Kingdom Department of Health Guidance on Physical Activity?
Joanna Robson¹, Karolina Lada², Anne Miller³, Wilby Williamson¹, Julia Newton² and Raashid Luqmani⁴, ¹Rheumatology, University of Oxford, Oxford, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³Nuffield Orthopaedic Center, Oxford., Oxford, United Kingdom, ⁴Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Physical inactivity is the fourth leading risk factor for global mortality accounting for 6% of deaths. Patients with giant cell arteritis (GCA) are at…
Abstract Number: 2925 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Early Damage Accrual in Patients with Systemic Lupus Erythematosus: 12-Month Preliminary Results from the Inception Cohort of the Multicenter Early Lupus Project
Matteo Piga¹, Fabiana Figus¹, Francesca Bellisai², Silvano Bettio³, Alessandra Bortoluzzi⁴, Laura Coladonato⁵, Fabrizio Conti⁶, Andrea Doria³, Mauro Galeazzi², Marcello Govoni⁴, Florenzo Iannone⁷, Annamaria Iuliano⁸, Marta Mosca⁹, Imma Prevete⁸, Gian Domenico Sebastiani⁸, Francesca Romana Spinelli¹⁰, Chiara Tani⁹ and Alessandro Mathieu¹, ¹University of Cagliari, Cagliari, Italy, ²University of Siena, Siena, Italy, ³Department of Medicine-DIMED, University of Padova, Padova, Italy, ⁴University of Ferrara, Ferrara, Italy, ⁵DIM, Rheumatology Unit, Bari, Italy, ⁶Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ⁷Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁸Osp. San Camillo, Roma, Italy, ⁹University of Pisa, Pisa, Italy, ¹⁰Sapienza University of Rome, Rome, Italy
Background/Purpose: Preventing organ damage is a major challenge in management of Systemic Lupus Erythematosus (SLE). Few data are available on factors related to development of…
Abstract Number: 293 • 2015 ACR/ARHP Annual Meeting
Measurement of Advanced Glycation Endproducts in the Skin of Patients with Idiopathic Inflammatory Myopathies
Simone Barsotti¹, Chiara Saponaro², Rosaria Talarico³, Alessandra Tripoli⁴, Claudia Ferrari⁵, Elisabetta Bianchini⁶, Nicole Di Lascio⁶, Melania Gaggini², Amalia Gastaldelli², Marta Mosca⁷, Maria Aurora Morales⁶ and Rossella Neri⁵, ¹Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²National Research Council, Institute of Clinical Physiology, Pisa, Italy, ³Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ⁴University of Pisa, Rheumatology Unit, Pisa, Italy, ⁵Internal Medicine, University of Pisa, Pisa, Italy, ⁶Institute of Clinical Physiology, CNR, Pisa, Italy, ⁷University of Pisa, Pisa, Italy
Background/Purpose: Many data suggest that advanced glycation endproducts (AGEs) play an important role the development of atherosclerosis and cardiovascular (CV) disease. AGEs are produced and…
Abstract Number: 1505 • 2015 ACR/ARHP Annual Meeting
Carotid Artery Atherosclerosis in Patients with Active Rheumatoid Arthritis: Predictors of Plaque Occurrence and Progression over 24 Weeks
Tatiana Nevskaya¹, Janet E. Pope², Lillian Barra³ and Grace Parraga⁴, ¹Medicine, Division of Rheumatology, University of Western Ontario, London, ON, Canada, ²University of Western Ontario, London, ON, Canada, ³Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ⁴University of Western Ontario, Robarts Research Institute, London, ON, Canada
Background/Purpose: This study evaluated the prevalence and progression of subclinical carotid artery atherosclerosis in active rheumatoid arthritis (RA). Methods: Carotid arteries of RA patients were scanned…
Abstract Number: 1568 • 2015 ACR/ARHP Annual Meeting
Cardiac Morphology and Function in Patients with Acute Coronary Syndrome Complicated with Rheumatoid Arthritis
Li-Li Pan¹ and Tian Wang², ¹Rheumatology and Immunology, Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China, ²1. Department of Rheumatology and Immunology,, Beijing An Zhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China
Background/Purpose: Cardiovascular diseases are important contributors to the excess of overall morbidity and mortality in patients with rheumatoid arthritis (RA). The aim of this study…
Abstract Number: 2126 • 2015 ACR/ARHP Annual Meeting
Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis
George D. Kitas¹, Peter Nightingale², Jane Armitage³, Naveed Sattar⁴, Jill Belch⁵, Deborah P.M. Symmons⁶ and TRACE RA Consortium, ¹Dudley Group NHS Foundation Trust, Dudley, and Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ²Wolfson Computer Laboratory, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Clinical Trial Service Unit and Epidemiology Unit, University of Oxford, Oxford, United Kingdom, ⁴University of Glasgow, BHF Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom, ⁵Division of Cardiovascular and Diabetes Medicine, University of Dundee, Dundee, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for cardiovascular disease (CVD) compared to the general population, both due to classical and novel…
Abstract Number: 3064 • 2015 ACR/ARHP Annual Meeting
Cardiac Manifestation of Takayasu Arteritis
Jin Wan, rheumatology and immunology, Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China
Background/Purpose: To explore cardiac manifestation of Takayasu arteritis and independent risk factor. Methods: We retrospectively analyzed manifestations and helpful tests in 55 TA patients. …
Abstract Number: 352 • 2015 ACR/ARHP Annual Meeting
Low Bone Density Is Associated with Atherosclerotic Disease in Patients with Psoriatic Arthritis
Eirik Ikdahl^1,2, Hege Kilander Høiberg³, Silvia Rollefstad², Andreas P Diamantopoulos^4,5, Grunde Wibetoe², Arthur Kavanaugh⁶, Inge C Olsen⁷, Tore K. Kvien⁷, Anne Grete Semb⁸ and Glenn Haugeberg⁹, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁴Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ⁵Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁶University of California San Diego, La Jolla, CA, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: There is an evidence vacuum concerning the mechanisms underlying the high atherosclerotic cardiovascular disease (ASCVD) burden in patients with psoriatic arthritis (PsA). In the…
Abstract Number: 1506 • 2015 ACR/ARHP Annual Meeting
EULAR Recommendations for Cardiovascular Risk Management in Patients with Rheumatoid Arthritis and Other Inflammatory Joint Diseases – 2015 Update
Michael T. Nurmohamed and on behalf of the EULAR task force "EULAR Recommendations for Cardiovascular Risk Management in patients with Rheumatoid Arthritis and other Inflammatory Joint Diseases", Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) (and other inflammatory joint diseases (IJD)) have an increased cardiovascular (CV) risk. In 2009 a EULAR taskforce recommended screening,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].